$28 M

AGRX Mkt cap, 04-Dec-2018
Agile Therapeutics Net income (Q3, 2018)-3.8 M
Agile Therapeutics EBIT (Q3, 2018)-3.6 M
Agile Therapeutics Cash, 30-Sep-201816.9 M

Agile Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

13.4m25.6m20.9m14.4m

General and administrative expense

5.2m7.5m8.8m12.4m

Operating expense total

18.5m33.1m29.7m26.8m

EBIT

(18.5m)(33.1m)(29.7m)(26.8m)

Interest expense

1.6m2.1m2.4m1.9m

Interest income

2.6k5.0k117.0k282.0k

Income tax expense

6.0m3.1m

Net Income

(16.1m)(30.3m)(28.7m)(28.3m)

Agile Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

40.2m34.4m48.8m36.0m

Accounts Receivable

539.0m

Current Assets

41.0m38.1m51.5m36.7m

PP&E

12.0m12.3m12.3m13.9m

Total Assets

54.8m50.7m63.9m50.6m

Accounts Payable

2.6m2.4m2.1m2.8m

Current Liabilities

9.0m7.9m10.7m14.3m

Total Liabilities

14.3m

Additional Paid-in Capital

170.4m194.5m235.8m258.1m

Retained Earnings

(134.4m)(164.7m)(193.5m)(221.8m)

Total Equity

36.0m29.7m42.3m36.3m

Financial Leverage

1.5 x1.7 x1.5 x1.4 x

Agile Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1m)(30.3m)(28.7m)(28.3m)

Depreciation and Amortization

12.6k18.0k19.0k23.0k

Inventories

(2.3m)(1.2m)922.0k

Accounts Payable

2.6m1.3m362.0k(2.5m)

Cash From Operating Activities

(14.5m)(25.5m)(23.3m)(24.6m)

Purchases of PP&E

(95.7k)(290.0k)(31.0k)(1.3m)

Cash From Investing Activities

(95.7k)(290.0k)(31.0k)(1.3m)

Cash From Financing Activities

52.7m20.0m37.7m13.1m

Interest Paid

1.4m1.5m1.5m

Agile Therapeutics Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information

Agile Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

45

Patents (US)

13

Phase I Trials Products

3

Phase II Trials Products

1

Phase III Trials Products

1
Report incorrect company information